Abstract
In order to test whether hyperlipidaemia and glycaemic control can be improved among diabetes patients by dietary supplementation with purified omega-3 fatty acids, we carried out a double-blind, placebo-controlled trial on 50 type 2 diabetes patients randomized to 2 g/day purified omega-3 fatty acids or placebo for 10 weeks. Fasting triglycerides decreased significantly with supplementation relative to placebo (P = 0.01). There was a significant decrease in ApoB-100 and malondialdehyde compared to baseline values and compared to the control group. Omega-3 fatty acids had no significant effect on serum lipid levels, ApoA-I, glucose, insulin and HbA1c.
Publication types
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Analysis of Variance
-
Apolipoproteins / blood*
-
Apolipoproteins / drug effects
-
Body Mass Index
-
Diabetes Mellitus, Type 2 / complications*
-
Diabetes Mellitus, Type 2 / metabolism
-
Dietary Supplements
-
Double-Blind Method
-
Fatty Acids, Omega-3 / pharmacology
-
Fatty Acids, Omega-3 / therapeutic use*
-
Female
-
Glycated Hemoglobin / drug effects
-
Glycated Hemoglobin / metabolism
-
Humans
-
Hyperlipidemias / blood
-
Hyperlipidemias / complications
-
Hyperlipidemias / prevention & control*
-
Insulin / blood
-
Iran
-
Lipids / blood*
-
Male
-
Malondialdehyde / blood*
-
Middle Aged
-
Statistics, Nonparametric
-
Treatment Outcome
-
Triglycerides / blood
Substances
-
Apolipoproteins
-
Fatty Acids, Omega-3
-
Glycated Hemoglobin A
-
Insulin
-
Lipids
-
Triglycerides
-
Malondialdehyde